|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
|
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash and cash equivalents | ||||||||
| Consolidated Sponsored Investment Products | ||||||||
| Total cash and cash equivalents | ||||||||
| Accounts receivable | ||||||||
| Investments | ||||||||
| Consolidated Sponsored Investment Products | ||||||||
| Total investments | ||||||||
| Separate account assets | ||||||||
| Separate account collateral held under securities lending agreements | ||||||||
| Property and equipment (net of accumulated depreciation and amortization of $1,852 and $1,692 at June 30, 2026 and December 31, 2025, respectively) | ||||||||
| Intangible assets (net of accumulated amortization of $1,989 and $1,482 at June 30, 2026 and December 31, 2025, respectively) | ||||||||
| Goodwill | ||||||||
| Operating lease right-of-use assets | ||||||||
| Other assets | ||||||||
| Consolidated Sponsored Investment Products | ||||||||
| Total other assets | ||||||||
| Total assets | ||||||||
| Liabilities | ||||||||
| Accrued compensation and benefits | ||||||||
| Accounts payable and accrued liabilities | ||||||||
| Borrowings | ||||||||
| Separate account liabilities | ||||||||
| Separate account collateral liabilities under securities lending agreements | ||||||||
| Contingent consideration liabilities | ||||||||
| Deferred income tax liabilities | ||||||||
| Operating lease liabilities | ||||||||
| Other liabilities | ||||||||
| Consolidated Sponsored Investment Products | ||||||||
| Total other liabilities | ||||||||
| Total liabilities | ||||||||
| Redeemable noncontrolling interests | ||||||||
| Consolidated Sponsored Investment Products | ||||||||
| Subco | ||||||||
| Total redeemable noncontrolling interests | ||||||||
| Permanent equity | ||||||||
| Common stock, $0.01 par value;Shares authorized: 500,000,000 at June 30, 2026 and December 31, 2025; Shares issued: 156,276,289 at both June 30, 2026 and December 31, 2025, Shares outstanding: 154,996,807and 155,069,171 at June 30, 2026 and December 31, 2025, respectively | ||||||||
| Additional paid-in capital | ||||||||
| Retained earnings | ||||||||
| Accumulated other comprehensive loss | ||||||||
| Treasury stock, common, at cost (1,279,482 and 1,207,118 shares held at June 30, 2026 and December 31, 2025, respectively) | ||||||||
| Total BlackRock, Inc. stockholders’ equity | ||||||||
| Nonredeemable NCI - CIPs | ||||||||
| Consolidated Sponsored Investment Products | ||||||||
| Total nonredeemable NCI - CIPs | ||||||||
| Total permanent equity | ||||||||
| Total liabilities, temporary equity and permanent equity |
Loading...
